Christopher Mantyh, MDColorectal surgeon
Associate Professor of Surgery/Chief, Gastrointestinal and Colorectal Surgery at Duke University Medical Center
Learn about Dr. Mantyh's clinical use of OFIRMEV and link to hear other experiences from your peers
Chris Pasero, MS, RN-BC, FAANPain management educator
Learn about the clinical use of OFIRMEV from pain management educator Chris Pasero and link to hear more from your peers
Take a closer look at the clinical data fromPain Study 1
Sinatra et al (Pain Study 1)
Randomized, double-blind, placebo-controlled, single- and repeated-dose 24-h study (n=101). Patients received OFIRMEV 1 g + PCA morphine or placebo + PCA morphine the morning following total hip or knee replacement surgery. Primary endpoint: pain relief measured on a 5-point verbal scale over 6 h. Morphine rescue was administered as needed. P<0.05 at every time point.
See how OFIRMEV + PCA morphine significantly reduced morphine consumption vs placebo + PCA morphine1
Sinatra et al (Pain Study 1)
Randomized, double-blind, placebo-controlled, single- and repeated-dose 24-h study (n=101). Patients received OFIRMEV 1 g + PCA morphine or placebo + PCA morphine the morning following total hip or knee replacement surgery. Primary endpoint: pain relief measured on a 5-point verbal scale over 6 h. Morphine rescue was administered as needed.
Cadence, OFIRMEV, and the OFIRMEV dot design are trademarks of Cadence Pharmaceuticals, Inc.
© 2013 Cadence Pharmaceuticals, Inc.
All rights reserved. OFV11410312
OFIRMEV (acetaminophen) injection is indicated for the management of mild to moderate pain; the management of moderate to severe pain with adjunctive opioid analgesics; and the reduction of fever.
OFIRMEV is contraindicated in patients with severe hepatic impairment, severe active liver disease or with known hypersensitivity to acetaminophen or to any of the excipients in the formulation. Acetaminophen should be used with caution in patients with the following conditions: hepatic impairment or active hepatic disease, alcoholism, chronic malnutrition, severe hypovolemia, or severe renal impairment.
Do not exceed the maximum recommended daily dose of acetaminophen. Administration of acetaminophen by any route in doses higher than recommended may result in hepatic injury, including the risk of severe hepatotoxicity and death.
OFIRMEV should be administered only as a 15-minute intravenous infusion.
Discontinue OFIRMEV immediately if symptoms associated with allergy or hypersensitivity occur. Do not use in patients with acetaminophen allergy.
The most common adverse reactions in patients treated with OFIRMEV were nausea, vomiting, headache, and insomnia in adult patients and nausea, vomiting, constipation, pruritus, agitation, and atelectasis in pediatric patients.
OFIRMEV is approved for use in patients ≥2 years of age.
The antipyretic effects of OFIRMEV may mask fever in patients treated for postsurgical pain.
To report SUSPECTED ADVERSE REACTIONS, contact Cadence Pharmaceuticals Inc. at 1‑877‑647‑2239 or FDA at 1‑800‑FDA‑1088 or www.fda.gov/medwatch.